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16 The Journal of Thoracic and Cardiobjective: Despite concern that small aortic valve prostheses can lead to prosthesis–
atient mismatch with diminished left ventricular mass regression and poor long-
erm outcome after aortic valve replacement, there remains reluctance to perform
ortic root enlargement procedures. We therefore examined the operative risks of
ortic valve replacement with and without root enlargement.
ethods: We reviewed perioperative outcomes among patients undergoing aortic
alve replacement at our institution between January 1993 and December 2001.
isk factors for operative death were evaluated by means of multivariable analysis.
esults: Of 2366 patients undergoing aortic valve replacement with (1173) or
ithout (1193) concomitant procedures, 249 (10.5%) underwent posterior root
nlargement. Patients undergoing complex root enlargement (Konno–Rastan pro-
edures) were excluded. Patients undergoing aortic root enlargement were signifi-
antly younger, twice as often female, and more often undergoing a reoperation but
ere similar with respect to functional class. The mean valve implant size was less
n the aortic root enlargement group (21.5  1.6 vs 23.2  2.3 mm, P  .0001). As
xpected, mean crossclamp time and bypass time were somewhat longer with root
nlargement. Raw operative mortality was higher with aortic root enlargement
5.6% vs 2.9%, P .0324); however, by means of multivariable analysis, advanced
unctional class (P  .0020; odds ratio, 1.87), preoperative congestive heart failure
P  .0001; odds ratio, 3.22), and smaller valve implant size (P  .012; odds ratio,
.16), but not aortic root enlargement, were independent risk factors for operative
eath.
onclusions: Aortic root enlargement itself does not increase operative risk, al-
hough it is most often required among high-risk patients. Surgeons should not be
eluctant to enlarge the aortic root to permit implantation of adequately sized valve
rostheses.
he surgical management of the small aortic root accordingly remains a
relevant topic. It is intuitive that one would elect to replace a stenotic
valve (or for that matter a regurgitant valve) with the least stenotic
rosthesis. Therefore, it is not surprising that a number of studies have demon-
trated superior left ventricular mass regression,1 postoperative functional class
nd exercise tolerance,2 and patient survival3 when small valves are avoided.
urthermore, prosthesis–patient mismatch (PPM)4 specifically has been shown
y some investigators to adversely affect left ventricular mass regression5,6 and
oth early and late survival.7-10
Other authors dispute the relevance of PPM in the current era, reporting little
r no relationship between valve orifice size and outcome.11,12 It has been
urther suggested that PPM is, in practice, quite uncommon.13 These arguments
vascular Surgery ● October 2007
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A
CDre complicated by various definitions of PPM ranging
rom an indexed orifice area of less than 0.6 cm2/m2,13 to
ess than 0.85 cm2/m2,11,12 as well as dispute over the
ore appropriate measure of orifice area (geometric or
ffective).
Although some physicians continue to debate the clin-
cal effect of aortic valve prosthesis size on outcome,
nterest in prosthetic hemodynamics persists. Indeed, su-
erior hemodynamic performance is the very basis of
any arguments in favor of the use of stentless xeno-
rafts and the Ross pulmonary autograft operation. Fur-
hermore, hemodynamic improvements remain a com-
on selling point among valve manufacturers, with
ach new-generation valve promising superior flow
haracteristics.
Regardless of academic argument, the practicing sur-
eon has a number of options available when confronted
ith the small aortic root and a circumstance in which he
r she wishes to implant a valve larger than the annulus
eadily accepts. Among those options is posterior aortic
oot enlargement (ARE). Many surgeons are reluctant to
erform ARE, however, out of concern that this adjunc-
ive procedure will increase operative morbidity and mor-
ality.14 This approach, however, has been our institu-
ional preference for management of the small annulus
ince Stenseth and colleagues15 first introduced it as an
pproach to prevent tertiary orifice obstruction after im-
lantation of the Starr–Edwards prosthesis. We find un-
ppealing the more complex alternatives promulgated
oday using stentless xenografts, homografts, or au-
ografts as full root replacements, a procedure associated
ith an almost 3-fold higher operative risk than simple
ortic valve replacement (AVR) in the Society of Thoracic
urgeons (STS) database (http://www.sts.org).16 We therefore
eviewed our experience with ARE among patients undergoing
VR with or without concomitant procedures.
aterials and Methods
atient Population
fter review and approval by the Mayo Clinic Rochester Insti-
utional Review Board, we retrospectively reviewed the clinical
ecords of 2366 consecutive adult patients undergoing AVR
rom January 1993 through December 2001. Of these, 249
Abbreviations and Acronyms
ARE  aortic root enlargement
AVR  aortic valve replacement
iEOA indexed effective orifice area
PPM  prosthesis–patient mismatch
STS  Society of Thoracic Surgeons10.5%) underwent posterior root enlargement. Only those o
The Journal of Thoracicases in which the operative note documented use of patch
aterial to accomplish root enlargement, as opposed to its use
o facilitate closure of a calcified or otherwise complicated
ortotomy, were included. Patients undergoing Konno–Rastan
rocedures were excluded, as were patients undergoing con-
omitant mitral valve repair or replacement, aortic aneurysm
epair, or composite aortic root reconstruction. Those undergo-
ng concomitant coronary artery bypass grafting were included
ecause they not only constituted a large fraction of both groups
ut also reflect the patient population in which the clinical
ecision to enlarge the annulus must be made in practice.
atients with other miscellaneous concomitant procedures, such
s tricuspid valve repair and atrial septal defect closure, the
ffect of which on mortality was deemed negligible, were
ncluded. All clinical data were collected prospectively accord-
ng to the guidelines and definitions of the STS database.
urgical Technique
perations were performed routinely under normothermic car-
iopulmonary bypass with intermittent cold blood cardioplegia.
here is no uniform policy in our unit with regard to minimum
cceptable prosthesis size, and opinions vary among surgeons.
f, however, the aortic annulus will not accept the valve size the
urgeon believes to be appropriate for the given patient, it is our
eneral preference to enlarge the annulus rather than implant a
tentless xenograft valve or homograft.
There is considerable confusion in the literature regarding
he techniques proposed by the eponymous descriptors Nicks’7
nd Manouguian’s17 enlargement. Key figures from the original
ontributions are therefore reproduced in Figure 1. Our tech-
ique is similar to that outlined by Nicks and associates.7 Our
tandard aortotomy for AVR is oblique, extending into the
oncoronary sinus. If the aortic annulus will not accommodate
he desired prosthesis, this aortotomy can be extended to but not
eyond the annulus because widening the apex with pericar-
ium permits implantation of a slightly larger valve by slightly
ilting the prosthesis such that the prosthetic sewing ring rides
bove the native annulus and is secured to the patch itself.
A somewhat greater enlargement can be accomplished by
xtending the incision in the base of the noncoronary sinus
eyond the aortic annulus onto the anterior mitral leaflet (Figure
, A). Once across the annulus, the incision is directed poste-
iorly toward the center of the anterior leaflet of the mitral
alve. A teardrop-shaped patch of autologous or bovine peri-
ardium is sutured to the base of the incision with a 4-0
olypropylene suture, with the broader end of the patch at the
pex. After completion of the suture line above the level of the
ivided annulus, the valve prosthesis is sutured in place in a
upra-annular position with 2-0 pledgeted Ethibond (Ethicon,
omerville, NJ) mattress sutures. In the region of the patch, the
utures are passed full thickness from outside the patch to
nside. The pericardial patch is then used to facilitate closure of
he aortotomy (Figure 2, B).
As a cautionary technical note, there is potential for im-
ingement of leaflet motion when a bileaflet mechanical pros-
hesis is implanted with this technique. Leaflet mobility must be
onscientiously inspected. Rotation of the prosthesis to obtain
ptimal valve closure is not uncommon.
and Cardiovascular Surgery ● Volume 134, Number 4 917
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CDtatistical Analysis
ategoric factors were compared between groups by using the
isher exact test, whereas continuous factors were compared by
sing Wilcoxon rank–sum tests. Univariate and multivariate
isk factors for operative mortality were evaluated by using
ogistic regression analysis. The final multivariate model was
onstructed with a stepwise selection technique.
esults
he clinical characteristics of the 2117 patients undergo-
ng AVR without ARE (AVR group) and the 249 patients
ndergoing AVR with ARE (ARE group) are shown in
able 1. The mean age in the ARE group was somewhat
ower than that of control subjects, and fewer had an
Figure 1. Original figures from articles published by Nic
(B) first describing posterior root enlargement technique
L. Hypoplasia of the aortic root. The problem of aortic v
permission from the BMJ Publishing Group. Figure 1B
enlargement of the aortic valve ring by extending the a
technique. J Thorac Cardiovasc Surg. 1979;78:402-12. Rjection fraction of less than 35%. The latter might in part p
18 The Journal of Thoracic and Cardiovascular Surgery ● Octoe due to the higher incidence of aortic regurgitation in
he AVR group. Patients undergoing ARE were twice as
ften female, however, and they had more often under-
one prior cardiac operations than had the control sub-
ects. Both groups were similar with regard to their
unctional class and the presence of endocarditis.
As might be anticipated, both aortic crossclamp time
nd cardiopulmonary bypass time were modestly pro-
onged in the ARE group (Table 2). Although other
oncomitant procedures were more common in the AVR
roup, ARE appeared to add only approximately 10 min-
tes to the mean myocardial ischemic time. Mechanical
alves were more often implanted in the ARE group,
d colleagues (A) and Manouguian and Seybold-Epting
gure 1A is reprinted from Nicks R, Cartmill T, Bernstein
replacement. Thorax. 1970;25:339-46. Reproduced with
printed from Manouguian S, Seybold-Epting W. Patch
incision into the anterior mitral leaflet. New operative
duced with permission from Mosby.ks an
s. Fi
alve
is re
ortic
eproerhaps reflecting the somewhat younger age of those
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A
CDatients and the superior hemodynamic results obtained
ith these valves.
As shown in Table 3, the incidence of postoperative
troke was similar in both groups, as was the incidence of
eoperation for bleeding. Raw operative mortality, how-
ver, was higher in the ARE group (5.6% vs 2.9%, P 
0324). When only isolated AVR procedures were con-
idered, the difference was slightly less and no longer
tatistically significant (4.5% vs 2.2%, P  .0953), al-
hough the trend remained.
Variables enlisted in the univariate and multivariate
odel for operative mortality are shown in Table 4.
rossclamp time and bypass time were not included
ecause it was expected that these would be strongly
ssociated with ARE. Univariate predictors of operative
ortality included ARE procedure, as well as age, sex,
ody surface area, and valve implant size, in addition to
ew York Heart Association functional class and history
f congestive heart failure. By means of multivariate
nalysis, however, only smaller valve implant size, pre-
perative functional class, and congestive heart failure
emained significant. When both groups were matched
or these significant variables, ARE was not a risk factor
Figure 2. A: a, Nicks’ aortic root enlargement is accomp
annulus into the anterior leaflet of the mitral valve. b, Care
of the anterior leaflet. c, The defect is closed with autolo
sutured in a supra-annular position. In the region of the
patch to inside. e, The pericardial patch is then used toor death. t
The Journal of ThoracicBecause the clinical decision regarding root enlarge-
ent is made among patients with small roots and pros-
hetic size itself was shown to be a risk factor in our
tudy, we made an effort to match cohorts with compar-
tive valve sizes. When a subgroup of patients with small
alves were considered (Table 5, A), the difference in
ortality rate was not statistically significant (7.1% vs
.5%, P  .2139), although again the trend remained.
ecause performing an ARE permits implantation of a
-size-larger valve, we also compared the group of pa-
ients with ARE and a valve size of less than 23 mm with
he subset of patients in the AVR group having 1 valve
ize smaller (ie, 21 mm). The trend for a difference in
ortality was smaller (6.0% vs 4.5%) and again not
tatistically significant (Table 5, B).
iscussion
ur data demonstrate that posterior ARE can be accom-
lished during AVR without significantly increasing op-
rative risk. Additionally, our findings confirm small
alve size as an independent risk factor for operative
ortality. Taken together, these findings support the con-
d by extending the aortotomy incision across the aortic
be taken to carry this incision posteriorly into the center
or bovine pericardium. Figure 2B: d, Valve prosthesis is
, the sutures are passed full thickness from outside the
tate closure of the aortotomy.lishe
must
gous
patch
faciliinued value of this approach as an option when a surgeon
and Cardiovascular Surgery ● Volume 134, Number 4 919
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A
CDishes to implant a larger prosthesis than the native
ortic annulus would otherwise accept.
These findings are consonant with those of other au-
hors. Sommers and David14 observed a statistically in-
ignificant trend toward a higher mortality rate among
atients undergoing ARE (7.1% vs 3.5%); however, sub-
equent studies by both Castro and colleagues18 and
itamura and associates19 reported mortality rates among
atients undergoing ARE that were actually lower than
hose observed among patients undergoing isolated AVR
2.5% vs 4.3% and 3.6% vs 5.9%, respectively). In none
able 1. Preoperative characteristics
ariable ARE AVR P value
o. 249 2117
ean age (y) 64.3 19.6 70.1 12.2 .006
ex
Male 72 (28.9%) 1408 (66.5%)
Female 177 (71.1%) 709 (33.5%) .0001
SA (m2) 1.92 1.20 1.98 0.25 .0001
rior cardiac operations
(redo)
78 (31.3%) 118 (5.6%) .0001
YHA class
1 9 (3.6%) 129 (6.1%)
2 39 (15.8%) 433 (20.5%)
3 171 (69.2%) 1250 (59.3%)
4 28 (11.4%) 297 (14.1) .1964
ndocarditis 2 (0.9%) 48 (2.3%) .1622
VEF 35% 14 (5.6%) 217 (10.6%) .0136
ortic valve lesion
Stenosis 84 (33.7%) 388 (18.3%) .0001
Insufficiency 10 (4.0%) 233 (11.0%) .0002
Mixed 153 (61.5%) 1482 (70%) .0072
RE, Aortic root enlargement; AVR, aortic valve replacement; BSA, body
urface area; NYHA, New York Heart Association; LVEF, left ventricular
jection fraction.
able 2. Operative details
ariable All ARE All AVR
ortic clamp time (min) 75.1 29.8 64.0 26.1
PB time (min) 116.5 53.5 93.6 40.5
oncomitant
procedures
101 (40.6%) 1072 (50.6%
CABG 85 (34.1%) 1037 (49.0%
Other 17 (6.8%) 68 (3.2%)
alve implant type
Mechanical 105 (42.2%) 806 (38.1%)
Bioprosthesis 144 (57.8%) 1311 (61.9%
ean  SD size
(range [median])
21.5  1.6 (19-25 [21]) 23.2  2.3 (17-33RE, Aortic root enlargement; AVR, aortic valve replacement; CPB, cardiopulmon
20 The Journal of Thoracic and Cardiovascular Surgery ● Octof these studies did multivariate analysis identify ARE as
risk factor for operative death.
Our findings also confirm the observations of others
hat small valve size is itself a risk factor for operative
eath,8,20,21 which might in part explain a higher ob-
erved mortality rate in the ARE group compared with
he AVR group because the procedure is required among
atients with a small annulus. The concept of PPM was
ormally introduced into the literature by Rahimtoola4 in
978. In theory, PPM exists to some degree whenever the
ffective orifice area of the prosthetic valve is less than
hat of the normal valve. In practice, this is the case, to a
reater or lesser extent, with almost all prosthetic op-
ions. Indeed, this was the rationale put forward by Nicks
nd colleagues7 in their original article on the subject of
RE. The disagreement on the subject concerns the clin-
cal effect of PPM. Some authors argue that PPM rarely
ccurs,13 and others argue that even if it is present, it is
f no clinical significance.11,12 Members of the opposing
amp cite data indicating inferior left ventricular mass
egression5,6 and reduced long-term survival9,10,20 among
atients with PPM. Our data do not, however, address
irectly the issue of PPM, and accordingly, we cannot
ake statements based on our study results concerning
he appropriate application of this technique. We can
nly document its low risk, particularly compared with
hat reported to the STS database for full root
eplacement.16
It should also be noted that arguments concerning
PM are complicated by disagreement over its definition.
erhaps not surprisingly, those who define PPM most
tringently as an indexed effective orifice area (iEOA) of
ess than 0.60 cm2/m2,13 report it to be a rare occurrence,
hereas others who define it as an iEOA of less than
.85 cm2/m2,11,12 report little effect on late survival.
ven more confusion is engendered by the various uses
f effective orifice area and geometric orifice area for
P value Isolated ARE Isolated AVR P value
.0001 70.6 27.5 51.4 19.8 .0001
.0001 106.3 47.5 73.9 30.2 .0001
.0031
.0001
.0102
68 (43.6%) 488 (46.3%)
.2157 88 (56.4%) 566 (53.7%) .5477
) .001 21.6  1.7 (19-25 [21]) 23.4  2.4 (17-33 [23]) .0001)
)
)
[23]ary bypass; CABG, coronary artery bypass grafting; SD, standard deviation.
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A
CDach of the very large number of valvular prostheses in
linical use. In an effort to account for this, a sophisti-
ated analysis performed by investigators at the Cleve-
and Clinic using multivariable propensity scores and
ultivariable hazard function analyses with bootstrap
esampling defined PPM in no less than 4 different man-
ers, including manufacturers’ labeled valve size, manu-
acturers’ stated internal orifice area, indexed internal
rifice area, and disease score as an expression of variant
f internal orifice area from the expected value.12 Re-
ardless, it is intuitive that an operation performed to
elieve valvular stenosis should leave the patient with the
east possible residual obstruction to flow. It is also clear
hat transvalvular gradients increase exponentially as the
EOA decreases to less than 0.8 to 0.9 cm2/m2.22
Table 3. Outcomes
Variable All ARE A
Stroke/TIA 8 (3.2%)
Reoperation for bleeding 12 (4.8%)
Perioperative myocardial infarction 1 (0.4%)
Pacemaker 10 (3.6%)
Operative mortality 14/249 (5.6%) 61/21
ARE, Aortic root enlargement; AVR, aortic valve replacement; TIA, trans
able 4. Predictors of operative mortality
ariable
Univariate Multivariate
P value OR P value OR
ge .0044 1.03
emale sex .0323 1.65
RE .0219 2.01
edo .4474 1.34
SA (per unit decrease) .0500 2.59
MI .5774 1.01
yocardial infarction .0236 1.93
ongestive heart failure .0001 4.62 .0001 3.22
revious operation .7572 1.12
revious AV surgery .8507 1.09
SR ( no) .0096 2.26
YHA .0001 2.52 .0020 1.87
VEF (per unit decrease) .0001 1.03
heumatic .8182 1.13
icuspid AV ( no) .0009 3.12
alcific AV ( no) .7604 1.11
rgent/emergency status .0619 2.15
alve implant size
(per unit decrease)
.0005 1.22 .012 1.16
reatinine 2.0 mg/dL .4958 1.19
R, Odds ratio; ARE, aortic root enlargement; BSA, body surface area;
MI, body mass index; AV, aortic valve; NSR, normal sinus rhythm; NYHA,
ew York Heart Association; LVEF, left ventricular ejection fraction. P
The Journal of ThoracicChoice among the 3 common techniques of root en-
argement can be dictated by individual surgeon experi-
nce, as well as complexity inherent to the procedure.
he Konno–Rastan procedure23,24 offers the greatest de-
ree of root enlargement. It is a complex procedure,
owever, requiring creation of a ventricular septal defect
nd right ventriculotomy, with double-patch closure of
oth. This risks damage to the septal arteries, as well as
he conduction system, and places the patient at risk of
ntercameral fistulae. The posterior root enlargement
echniques described by Nicks and colleagues7 and Man-
uguian and Seybold-Epting17 are more straightforward
echnically, although arguments have been made con-
erning impedance to outflow imposed by angular distor-
ion of the left ventricular outflow tract with overriding of
he prosthesis on the anterior leaflet of the mitral valve.
hoice between Nicks’ and Manouguian’s enlargement
ill likely be largely dictated by the surgeon’s preferred
ortotomy, oblique or transverse, with the former en-
argement representing an extension of the oblique and
he latter an extension of the transverse approach (Figure
). Both techniques as originally described cross the
urgical annulus, although as commonly applied they
ight not.
P value Isolated ARE Isolated AVR P value
.1%) .8485 6 (3.9%) 25 (2.4%) .2754
.5%) .8721 4 (4.3%) 39 (3.7%) .7731
.3%) .5898 0 (0.0%) 2 (0.2%) 1.000
.6%) .7197 8 (5.1%) 36 (3.4%) .2580
.9%) .0324 7/156 (4.5%) 23/1054 (2.2%) .0953
chemic attack.
able 5A. Valve size <21 mm
ortality ARE AVR Total
o 143 (92.9%) 594 (95.5%) 737
es 11 (7.1%) 28 (4.5%) 39
otal 154 622 776
 .2139. ARE, Aortic root enlargement; AVR, aortic valve replacement.
able 5B. ARE <23 mm vs ARV <21 mm
ortality
ARE, valve
size <23 mm
AVR, valve
size <21 mm Total
o 218 (94%) 594 (95.5%) 812
es 14 (6%) 28 (4.5%) 42
otal 232 622 854ll AVR
66 (3
96 (4
7 (0
76 (3
17 (2 .3750. ARE, Aortic root enlargement; AVR, aortic valve replacement.
and Cardiovascular Surgery ● Volume 134, Number 4 921
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A
CDOur study had significant limitations. Despite being
he largest study of its kind in the literature, the number
f patients in the study remains relatively small. Our
ailure to assign statistical significance to the observed
ifference in mortality might therefore be due to insuf-
cient power. Furthermore, because the study includes
atients operated on by a large number of surgeons
ithout a rigidly defined institutional philosophy regard-
ng acceptable prosthesis size, details of the decision-
aking process regarding ARE are vague. This does not,
owever, weaken the empiric observations reported. Fi-
ally, as noted above, our data address only one half of
he risk– benefit equation determining the indications for
RE. With absent data concerning the effect of PPM on
emodynamic outcome, we cannot argue the place of
RE in the surgeon’s armamentarium nor justify its use
n particular circumstances. Furthermore, we do not have
emodynamic measures of the effectiveness of posterior
RE in relieving the outflow gradient. Indeed, one could
rgue that the procedure as performed failed to provide
ufficient annular enlargement because valve size re-
ained a predictor of operative mortality. This might in
art be due to inconsistency among surgeons with regard
o extension of the enlargement across the true annulus.
onetheless, our data do satisfactorily address the issue
f incremental operative risk imposed by application of
his approach.
We conclude that ARE using the Nicks technique can
e accomplished with low operative risk, and accord-
ngly, surgeons should not be reluctant to do so when
hey believe it is otherwise clinically indicated.
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r David A. Fullerton (Denver, Colo). Dr Dhareshwar, I
ould like to compliment you both on a very crisp and clear
resentation and also on an extremely well-written manuscript.
hank you very much for forwarding that to me, as well as a
opy of your presentation.
I liked your topic, your presentation, and your article in large
art because it fits my bias perfectly. I have to acknowledge that
have a very low threshold for enlarging the annulus, and
herefore it is pleasing to see your data, particularly in light of
he background literature on the subject.
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CDAcknowledging that in your analysis the annular enlargement
er se did not fall out as an independent risk factor for perioper-
tive death, small valve size did. I am curious as to what your
nsight might be as to why that is the case.
Dr Dhareshwar. In our data set, if you look at the range of
reoperative annulus sizes, almost 60 patients had an annulus
ize of less than 19 mm, which means we could not even get the
9-mm valve in place. Even after an ARE, the valve size that we
ould implant was 19 mm in almost 43 patients. With the large
roportion of patients having a very small aortic annulus, in our
tudy that turned out to be a more significant risk factor than
nnular enlargement per se.
Dr Fullerton. But according to your article, and I realize I
m taking you beyond the analysis of this talk, among those
ho did not have an annular enlargement, there was a substan-
ial percentage who actually received small valves. That led me
o wonder what the indications were, if you know, for actually
nlarging the annulus.
Dr Dhareshwar. I think it all depends on the clinical judg-
ent at the time of the operation. Although everybody tries to
mplant the largest valve size possible, and we have in our
inds when we go into the operating room a minimum size
alve we are willing to place, sometimes it is not possible to
nlarge the annulus. Presumably the surgeon believed annular
nlargement was not needed in that particular patient.
Dr Fullerton. Given the fact that this is a retrospective
eview, am I safe to assume then that there is no protocol-driven
lgorithm for addressing the size of the anticipated implanted
rosthesis as a function of the patient’s body surface area?
Dr Dhareshwar. It is based on the individual surgeon. We
lways take into account the general body surface area and how
he patient looks, his age, and the comorbidities. If the life
xpectancy is not that long—if we are doing a case on an
5-year-old patient, aortic annular enlargement might not be
eeded in that patient. It is a clinical judgment, and I think it has
o be individualized to the patient.
Dr Fullerton. One final question. You indicated on your
onclusion slide that you do not have long-term follow-up, but
he literature would suggest that among patients who are given
n AVR and who are left with an effective orifice area to body
urface area ratio of less than about 0.8 cm2/m2, the classic
efinition of PPM, it turns out, to my surprise, that the survival
urves for those 2 situations do not begin to diverge until about
or 8 years after the operation. Given the size of your database
nd the magnitude of your experience, I am curious to know
hether you have any insight into that.
Dr Dhareshwar. We are working on that. It is one of the
ifficulties that we face when we look at the relationship
etween an effective orifice area rather than the valve size per
e. Over the period of 9 years from 1993-2001, we had more
han 15 different valves implanted. We have now restricted
urselves to 3 or 4 valve types, and it will be easier to predict
he effective orifice area based on in vivo Doppler studies. We
id not want to use geometric orifice areas, which we believe
an be misleading. We would prefer to use iEOA based on
oppler studies in vivo. We hope that given the fewer valves u
The Journal of Thoracichat we have used over the last 8 to 10 years or so, in a couple
f years we should have long-term data in these patients.
Dr Fullerton. Thank you very much.
Dr Dhareshwar. Thank you.
Dr D. Craig Miller (Stanford, Calif). I have been trying to
cratch the foggy catacombs of my brain, but you called this a
icks, and if I remember correctly from 30 years ago, it is not
Nicks at all. A Nicks is done in the commissure between the
ight and the noncoronary sinus, the membranous septum. This
s what most of us would call a hemi-Manouguian. Are there
ny historians or old-timers in the room who could clarify that?
Dr Sundt. Craig, there is often confusion on this. Manou-
uian’s enlargement is through the commissure between the left
nd noncoronary sinus, and Nicks is at the base of the noncoro-
ary sinus.
Dr Miller. He was an Australian surgeon, right? Okay. I
tand corrected. Thank you. Manouguian does go through the
ommissure between the left and noncoronary sinus.
Dr Sundt. Does that go down in the record books at the
estern? (laughter).
Dr Miller. I am wrong 100 times a day. So the Manouguian
s between the commissure between the left and the noncoro-
ary sinus, and the Nicks is right in the belly of the noncoronary
inus?
Dr Sundt. That is right.
Dr Miller. Okay, I stand corrected, and I think we all stand
marter.
Dr Sundt. Wait, the president says I am wrong, too. Scott?
Dr Mitchell. I hate to pull rank and disagree with Craig, but
ctually, the Manouguian I think stops just through the annulus,
ut the Nicks does not go onto the anterior leaflet. It stops
efore it goes across the annulus. Therefore this is probably a
ombination of the Nicks and Manouguian.
Unidentified speaker. I enjoyed your presentation. When
ou analyzed your data, did you look at patients who still had
residual mismatch after the enlargement, and did you analyze
t with respect to mechanical versus stented tissue valves?
econd, in the era of homografts and stentless tissue valves,
hat is your current indication for doing a root enlargement in
hese patients?
Dr Dhareshwar. That is an excellent question. Unfortu-
ately, as I said before, we did not have a lot of data on the
ffective orifice areas, given more than 15 different valve types,
nd therefore we did not look at existing or residual PPM in
hese patients, but we hope that in subsequent studies we can
ook at that. There is no difference between the bioprosthesis
nd the mechanical valves.
Regarding homografts and stentless valves, our bias is to-
ard performing root enlargement preferentially over stentless
alves. We currently use homografts in the pediatric population
nd in adults only if we are faced with the situation of endo-
arditis. Very rarely do we use stentless valves when we think
hat the patient needs a root replacement for aneurysm on
issection rather than just an AVR, and therefore we are biased
oward a root enlargement and getting in a larger valve than
sing stentless valves.
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A
CDDr Benjamin Youdelman (Philadelphia, Pa). In your study
ou looked at 15 different types of valves. The data I am
resenting at this meeting comparing 8 common valves shows
range of 1.5 to 0.5 mm between the measured size and the
abeled valve size, and I suspect there would be a similar range
ver your 15 different valves. I would argue that your analysis24 The Journal of Thoracic and Cardiovascular Surgery ● Octose geometric orifice area. I would also argue that effective
rifice area should not be used because of the variability in
easurements that is likely caused by differences in heart rate,
lood pressure, ventricular function, and echocardiographic
ata acquisition.
Dr Dhareshwar. I agree with your comments. I also had a
hould not be done using labeled valve size but that you should look at your poster. It is a nice poster.ber 2007
